Calcitonin in Human Serum
- 1 June 1972
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of internal medicine (1960)
- Vol. 129 (6) , 889-893
- https://doi.org/10.1001/archinte.1972.00320060037002
Abstract
Calcitonin released from the thyroid gland (thyrocalcitonin, TCT) inhibits parathyroid hormone (PTH)-stimulated bone resorption in tissue culture. This effect can be used to assay TCT-like activity in human serum. Assays were negative in normal subjects, even after a calcium infusion. Assays were often positive after calcium infusion in patients with hypocalcemia. Serum samples from patients with metabolic disorders of bone were usually negative. Serum TCT-like activity was high in five patients with medullary carcinoma of the thyroid. Calcium infusion increased activity in only two of these patients. Infusion of edetate sodium decreased activity, but long-term administration had no effect. In uncomplicated medullary carcinoma serum calcium and phosphate concentrations were normal and serum PTH by immunoassay was minimally elevated.This publication has 8 references indexed in Scilit:
- Detection of Thyrocalcitonin in Rat Serum by Direct Tissue Culture BioassayEndocrinology, 1970
- Thyrocalcitonin: Evidence for Physiological FunctionScience, 1969
- Effect of Phosphate, Calcium and Magnesium on Bone Resorption and Hormonal Responses in Tissue CultureEndocrinology, 1969
- Hypocalcemic Activity of Serum in Patients with Medullary Carcinoma of the ThyroidAmerican Journal of Clinical Pathology, 1969
- Thyrocalcitonin.Physiological Reviews, 1969
- A Case of Tertiary Hyperparathyroid CrisisThe Lancet Healthy Longevity, 1968
- SPECIES DISCRIMINATION BETWEEN CALCITONINSThe Lancet, 1968
- Pseudohypoparathyroidism: assays of parathyroid hormone and thyrocalcitonin.Proceedings of the National Academy of Sciences, 1966